We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Gilead Sciences' important HIV business has been under fire in recent weeks, with lawsuits and critics airing allegations about the company’s pricing, patents and more.